INTERNATIONAL JOURNAL IN PHARMACEUTICAL SCIENCES

Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Advancements In Pharmacotherapy for Myocardial Infarction: A Comprehensive Review

SATISH S., ARAVIND BABU C.*

Department of Pharmacy Practice, Srinivas College of Pharmacy, Manglore-574143.

ARTICLE INFO

Received: 14 Dec 2023
Accepted: 17 Dec 2023
Published: 19 Dec 2023

Keywords:
Myocardial infarction, ischemic heart disease

DOI:
10.5281/zenodo.10405404

ABSTRACT

Cardiovascular disease (CVD) remains a global health concern, accounting for a significant portion of annual deaths. Myocardial infarction (MI) and ischemic stroke contribute substantially to CVD-related mortality. Despite decades of research, cardiac repair post-MI remains challenging. The immune system's pivotal role in the aftermath of MI initiates inflammation crucial for tissue healing, yet excessive inflammation may hinder left ventricle remodeling, leading to heart failure. This comprehensive systematic review explores the pathophysiology of MI, emphasizing the importance of understanding coronary artery occlusion-induced myocardial necrosis and subsequent healing processes. The clinical manifestations of MI, including ST-segment elevation and non-ST-segment elevation scenarios, are delineated alongside risk factors, genetic predispositions, and variable symptomatology. First-line treatments, such as oxygen therapy, nitroglycerin, and reperfusion therapy, are examined. The efficacy and safety of oxygen therapy are scrutinized, challenging its routine use. Nitroglycerin, once contraindicated, is reassessed, particularly in specific MI subgroups. Reperfusion therapy, while reducing mortality, poses risks, prompting exploration into device-based therapies to mitigate side effects. Antiplatelet therapy, including aspirin and P2Y12 inhibitors, assumes a critical role in MI treatment. Aspirin's controversial role in primary prevention is juxtaposed with its established benefits in secondary prevention. Beta-blockers, long recommended post-MI, exhibit varied outcomes in contemporary patient populations, necessitating further research. The review delves into the pivotal roles of anticoagulants, statins, and ACE inhibitors/ARBs in preventing recurrent events post-MI. Personalized medicine emerges as a key consideration in tailoring treatment plans to individual patient characteristics.

***Corresponding Author:** Aravind Babu C

Address: *Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Farangipete Post, Manglore-574143, Karnataka, India.*

Email ✉: aravindapooskvr@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for an estimated 17.9 million deaths annually, or 31% of all deaths. Of all the deaths related to CVD, MI and ischemic stroke account for four of every five deaths. These figures highlight the critical need for appropriate interventions to improve the prognosis and chances of survival for patients with CVD.[1] Ischemic heart disease continues to be one of the world's leading causes of death, and cardiac repair following myocardial infarction (MI) injury remains a challenge despite decades of research.[2]Myocardial infarction (MI) and ischemic stroke account for four out of every five deaths linked to CVD.[1] In the process that follows a MI, the immune system is crucial. A strong inflammatory cell infiltration is started in the heart to eliminate the dead tissue as soon as an ischemic injury takes place. While this is required for the myocardium to heal, excessive or ongoing inflammation can have a negative impact on the remodeling of the left ventricle (LV) and cause heart failure.[2] The term "heart attack" refers to myocardial infarction (MI), which is the result of reduced or stopped blood flow to a section of the myocardium. An MI could be "silent" and go unnoticed, or it could be a catastrophic event that results in hemodynamic decline and abrupt death. coronary artery disease, is the root cause of the majority of myocardial infarctions. Oxygen is not available to the myocardium when coronary artery blockage occurs. Long-term oxygen supply deprivation of the heart can result in necrosis and death of heart cells. Patients may exhibit pressure or discomfort in the chest, which may radiate to the jaw, arm, neck, or shoulder.Myocardial ischemia can be linked to elevated biochemical markers like cardiac troponins and changes in the electrocardiogram in addition to the history and physical examination.[3] ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) are the two clinical settings for MI. The electrocardiogram (ECG) exhibits distinctive abnormalities that are indicative of STEMI [14]. The characteristic elevation in the "ST segment," also known as STEMI, is one of those ECG abnormalities. Instead, non-ST-segment elevation myocardial infarction (NSTEMI) is defined as the presence of positive cardiac biomarkers like troponin without ST-segment elevation.[4] Genetic predisposition and non-genetic variables like lifestyle choices, diabetes, obesity, and high blood pressure are the primary risk factors for MI Numerous studies have demonstrated that smoking is associated with a poor prognosis for MI as well as an increased risk factor for the onset of MI . According to certain other research, smoking has no discernible impact on the onset or prognosis of MI . High levels of physical activity (PA) have been shown to protect MI patients from a 1-year readmission due to non-cardiovascular disease . Additionally, PA reduces the likelihood of MI.Premature coronary artery disease in the family is a significant risk factor for MI development. [5]Although breathlessness and chest pain are the typical signs of a heart attack, there can be a wide range of symptoms.[6]

The other symptoms include shortness of breath, perspiration, nausea, vomiting, irregular heartbeat, anxiety, exhaustion, weakness, stress, depression. it’s important to note that not all people who have heart attacks experience the same symptoms or the same severity of symptoms[7].

PATHOPHYSIOLOGY:

MI is characterized by the occlusion of coronary arteries, which results in the necrosis of cardiac cells from a decreased oxygen supply[8] . Myocardial infarction (MI) is caused by thrombotic occlusion of a coronary vessel due to rupture of a vulnerable plaque, leading to sudden ischemic death of myocardial tissue [9]. Ischemia induces metabolic and ionic perturbations in the

affected myocardium, resulting in rapid depression of systolic function [10]. Prolonged myocardial ischemia triggers cardiomyocyte death, which extends from the subendocardium to the subepicardium [11]. Mitochondrial alterations play a significant role in apoptosis and necrosis of cardiomyocytes in the infarcted heart [12]. The healing process of the infarcted myocardium involves an inflammatory cascade triggered by alarmins released by dying cells [13]. Clearance of dead cells and matrix debris by infiltrating phagocytes activates anti-inflammatory pathways, leading to suppression of cytokine and chemokine signaling . Activation of the renin-angiotensin-aldosterone system and release of transforming growth factor-β promote deposition of extracellular matrix proteins, contributing to scar formation . Infarct healing is associated with geometric remodeling of the chamber, characterized by dilation, hypertrophy of viable segments, and progressive dysfunction .

FIRSTLINE TREATMENT:

1. OXYGEN THERAPY:

It is commonly advised that patients with myocardial infarction take oxygen (O-2). Numerous investigations have been carried out to evaluate the safety and efficacy of oxygen therapy in patients with MI. According to a systematic review and meta-analysis, oxygen inhalation may raise the risk of recurrent MI and was not beneficial for MI patients with normal oxygen saturation [14]. Hyperbaric oxygen therapy (HBOT) was linked to better perfusion and an increased ejection fraction in a different study that compared it to standard care for STEMI patients [15]. On the other hand, routine use of supplemental oxygen did not significantly affect clinical outcomes in normoxemic STEMI patients undergoing primary percutaneous coronary intervention, according to a randomized clinical trial [16].Routine oxygen therapy did not provide any clinical benefit for MI patients without baseline hypoxemia, according to another registry-based randomized clinical trial [17]. Overall, the data point to the possibility that routine oxygen therapy use in MI patients may not be advantageous, and more investigation is required to ascertain the treatment's place in clinical practice.

2. NITROGLYCERINE

Nitroglycerin remains a first-line treatment for angina pectoris and acute myocardial infarction. Although nitroglycerin was previously considered contraindicated because of the risk of lowering arterial blood pressure and causing cardiogenic shock, new research indicates that nitroglycerin may be beneficial in some subgroups of MI patients. In regions with reduced coronary flow, intravenous nitroglycerin has been demonstrated to lower left ventricular filling pressure and enhance regional ventricular function[18]. Furthermore, it has been discovered that low-dose intravenous nitroglycerin infusion is safe and can enhance hemodynamics, shrink the size of the infarct, and lessen complications and fatalities in individuals suffering from acute MI [19]. Additionally, extended nitroglycerin therapy following a MI may be beneficial, according to preliminary research. It is crucial to remember that research on the use of nitroglycerin for myocardial infarction is still ongoing, and each patient must be evaluated individually [20].

3. REPERFUSION THERAPY

For patients with myocardial infarction (MI), reperfusion therapy is a standard course of treatment. Following acute MI, it has been demonstrated to lower mortality and heart failure. Reperfusion, however, has the potential to cause myocardial damage, and the clinical events following acute MI are largely influenced by microvascular blockage as well as ischemia-reperfusion injury [21]. A number of device-based therapies, such as vagal stimulation, myocardial cooling, mechanical cardiac unloading, coronary

sinus interventions, and supersaturated oxygen therapy, have been investigated to decrease infarct size . These methods provide special chances to target ischemia-reperfusion injury and can alter the biology of ischemic myocardium prior to reperfusion [22].Inflammatory mediators have distinct functions in myocardial ischemia reperfusion injury (MIRI), where they can both exacerbate damage resulting from myocardial infarction and repair damage. A constant focus is on the investigation and creation of medications for the prevention and management of MIRI.

4. ANTIPLATLET THERAPY

4a.ASPIRIN

Aspirin is usually given as soon as a heart attack is suspected.For secondary prevention, aspirin is frequently used in the treatment of myocardial infarction (MI). In patients who have survived a previous occlusive vascular event, it has been demonstrated to significantly lower the risk of subsequent MI, stroke, and vascular death [23]. Nevertheless, there is conflicting evidence regarding aspirin's role in MI primary prevention [24]. Aspirin has been shown to lower platelet reactivity in patients with cardiovascular disorders and is also used as an antiplatelet therapeutic medication in secondary prevention [25].Furthermore, studies conducted recently have demonstrated the potential benefits of aspirin-exacerbated respiratory disease (AERD), which is typified by nasal polyposis, chronic rhinosinusitis, and adult-onset asthma, to be treated with aspirin desensitization and maintenance therapy [26] . Aspirin is essential for treating MI and other cardiovascular diseases overall, but using it for primary prevention necessitates carefully weighing each person's risk-benefit ratio.

4b.P2Y12 INHIBITORS:

Many studies have been conducted on P2Y12 therapy for the treatment of myocardial infarction (MI). The effect of pretreatment with a P2Y12 inhibitor on thrombotic and hemorrhagic endpoints in patients with ST-elevation MI (STEMI) receiving percutaneous coronary intervention (PCI) has been examined in a number of studies . These studies' findings imply that pretreatment with oral P2Y12 inhibitors prior to PCI in STEMI patients did not appear to be linked to a lower risk of major bleeding, myocardial infarction, or all-cause mortality[27].Pretreatment with P2Y12 inhibitors, however, seems to help lower the risk of reinfarction in the pre-hospital context .Furthermore, pretreatment with p2y12 inhibitors in NSTEMI patients undergoing invasive management was linked to an increase in major and minor bleeding complications during hospitalization, but it did not lower the rate of periprocedural myocardial infarction and myocardial injury. All things considered, the specific clinical situation and patient characteristics should be taken into account when using p2y12 inhibitors to treat myocardial [28].

5. BETA BLOCKERS

For a long time, beta blockers have been advised as a treatment for myocardial infarction (MI). Beta blockers such as metoprolol ,carvedilol or bisoprolol are typically initiated within the first 24 hours after MI. They reduce myocardial oxygen demand ,limit infract size and decrease the risk of arrhythmias and recurrent ischemic events.Guidelines for clinical practice have endorsed their use in all patients who do not have any contraindications [29]. In addition to lowering myocardial oxygen demand and preventing arrhythmias, beta blockers also enhance ventricular remodeling [30]. Research has demonstrated that after acute MI, beta blockers can lower the risks of cardiovascular mortality, major cardiovascular events, myocardial reinfarction, and all-cause mortality in patients without heart failure . The true results, however, could differ significantly, and the evidence is of moderate to low certainty . The studies that made up the analysis were carried out before reperfusion

therapy was commonly used, and it is still unknown how beta blockers would affect patients undergoing primary percutaneous coronary intervention [31]. To properly evaluate the advantages and disadvantages of beta blockers in modern patients without heart failure after acute MI, more research is required, especially in older patients and with an emphasis on serious adverse events and quality of life[32] .

6. ANTICOAGULANTS

When combined with antiplatelet therapy, anticoagulants play a critical role in improving outcomes for patients suffering from ST-segment elevation myocardial infarction (STEMI) [33]. They are useful in lowering death and recurrent ischemic events, such as myocardial infarction and stent thrombosis [34]. The treatment of acute myocardial infarction, percutaneous coronary intervention, stroke prophylaxis in atrial arrhythmia patients, and patients with mechanical heart valves are all impacted by anticoagulation [35]. Anticoagulants have a long history of use in the treatment of myocardial infarction, and their efficacy in preventing thromboembolic conditions has been demonstrated [36].

7. STATIN

A number of randomised controlled trials have shown that treating statins can prevent recurrent MI[37].High-intencity statin therapy,such as atorvastatin or rosuvastatin,is initiated early in MI management. Statins are hydroxymethylglutaryl-CoA reductase inhibitors that have been shown to have a variety of pleiotropic benefits, including antioxidant, thrombolytic, and anti-inflammatory effects[38].As a result, statins are thought to be a key component in the prevention of MI. According to certain research, taking statins before treating MI significantly lowers the risk of the condition.Nevertheless, additional clinical research revealed that taking statins at an early age did not lower the risk of MI[39].Other clinical research, however, revealed that patient adherence to the statin may be crucial and that the pleiotropic effect was not diminished by early statin use. Reperfusion injury and MI size in AMI may be reduced by the pluripotent effects of statins, which include reducing inflammation, preventing platelet aggregation, enhancing endothelial function, activating endothelial progenitor cells, and boosting plaque stability. The significance of early statin initiation is further supported by evidence that pre-procedural high-dose statin in ACS improves microvascular myocardial perfusion and reduces infarct size[40].

8. ACE Inhibitors and ARBs

ARBs and ACE inhibitors are frequently used to treat myocardial infarction (MI). In patients with diabetes, ACE inhibitors help reduce heart failure (HF), MI, cardiovascular (CV) deaths, and the composite outcome of CV events. In patients with non-ST-segment elevation myocardial infarction (NSTEMI), however, ARBs have been linked, in comparison to ACE inhibitors, to an increased risk of major adverse cardiac events (MACEs), any repeat revascularization, and target vessel revascularization (TVR) [41]. Compared to ARBs, ACE inhibitors have demonstrated a decrease in all-cause death in patients with dyslipidemia who have experienced an acute myocardial infarction (AMI). As a result, in the treatment of MI, ACE inhibitors are typically chosen over ARBs due to their demonstrated ability to lower mortality and enhance clinical outcomes[42].

SUMMARY

Myocardial infarction (MI), in particular, is still one of the main causes of death worldwide due to cardiovascular disease. Although the immune system plays a critical role in the inflammatory response that follows MI, too much inflammation can have a negative impact on cardiac remodeling and heart failure. MI, also referred to as a heart attack, is caused by a decrease in blood flow to a particular area of the heart. The risk of MI is influenced by genetic and lifestyle factors, and

symptoms can differ greatly. The pathophysiology is coronary artery occlusion, which results in reduced oxygen delivery to the heart and necrosis of the heart cells.Reperfusion therapy, nitroglycerin, and oxygen therapy are first-line treatments for MI. The advantages of oxygen therapy are being questioned, and the use of nitroglycerin for particular MI subgroups is being reexamined. Even though reperfusion therapy lowers mortality, there are risks involved, so different device-based therapies are being investigated. In the treatment of MI, antiplatelet therapy—such as aspirin and P2Y12 inhibitors—is essential. Although aspirin's usefulness in primary prevention is debatable, it is commonly used in secondary prevention. Although more research is required, beta-blockers are advised post-MAn essential part of managing MI is taking statins, ACE inhibitors/ARBs, and anticoagulation. Statins have pleiotropic benefits, but anticoagulants reduce death and recurrent ischemic events. Because they reduce mortality more than ARBs, ACE inhibitors are preferred. The review highlights the necessity of continuing research to improve treatment approaches, particularly in light of changing patient demographics and clinical practices.I to lower myocardial oxygen demand, restrict the size of infarcts, and avoid arrhythmias.

CONCLUSION

The field of pharmacotherapy for myocardial infarction has witnessed significant advancements over the years, contributing to improved outcomes and enhanced patient care. Key developments include the widespread use of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and statins in the management of acute coronary syndromes. Novel anticoagulants, such as direct oral anticoagulants (DOACs), have emerged as alternatives to traditional therapies, offering comparable efficacy with reduced bleeding risks. Additionally, the advent of precision medicine has paved the way for tailored treatment approaches based on individual patient characteristics and genetic factors. The integration of reperfusion strategies, including primary percutaneous coronary intervention (PCI) and thrombolytic therapy, has become standard practice in the early management of myocardial infarction, further improving survival rates and minimizing cardiac damage.

Ongoing research continues to explore innovative therapeutic targets, including novel anti-inflammatory agents and gene therapies, with the aim of further optimizing myocardial infarction outcomes. As we move forward, a comprehensive and multidisciplinary approach that combines pharmacotherapy with lifestyle modifications and patient education remains crucial for preventing and managing myocardial infarction effectively.

It is essential for healthcare professionals to stay abreast of these advancements, ensuring the translation of scientific progress into improved clinical care and outcomes for patients with myocardial infarction.

REFERENCES

1. Golforoush P, Yellon DM, Davidson SM. Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Res Cardiol. 2020 Nov 30;115(6):73
2. Viola M, de Jager SCA, Sluijter JPG. Targeting Inflammation after Myocardial Infarction: A Therapeutic Opportunity for Extracellular Vesicles? Int J Mol Sci. 2021 Jul 22;22(15):7831
3. Ojha N, Dhamoon AS. Myocardial Infarction. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-
4. Jayaraj JC, Davatyan K, Subramanian SS, Priya J. Epidemiology of Myocardial Infarction [Internet]. www.intechopen.com. IntechOpen; 2018.

5. Zhan C, Shi M, Wu R, He H, Liu X, Shen B. MIRKB: a myocardial infarction risk knowledge base. Database (Oxford). 2019 Jan 1;2019:baz125. doi: 10.1093/database/baz125. PMID: 31688939; PMCID: PMC6830040
6. Macon L. Acute Myocardial Infarction [Internet]. Healthline. Healthline Media; 2012.
7. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015 Jul;72(3):865-7
8. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology [Internet]. 2018 Dec;25(4):277–84.
9. Frangogiannis NG. Pathophysiology of Myocardial Infarction. Comprehensive Physiology [Internet]. 2015 Sep 20;5(4):1841–75.
10. Al-Botaty B, El-Khoely A, Elsayed E, Eissa A. Insight into the Pathophysiology of Myocardial Infarction. Journal of Advanced Pharmacy Research. 2022 Oct 1;6(4):223–37.
11. Pepine CJ. New concepts in the pathophysiology of acute myocardial infarction. American Journal of Cardiology [Internet]. 1989 Jul 18 [cited 2020 May 26];64(4):2B8B.
12. Landesberg G. The pathophysiology of perioperative myocardial infarction: Facts and perspectives. Journal of Cardiothoracic and Vascular Anesthesia. 2003 Feb;17(1):90–100.
13. Skyschally A, Schulz R, Heusch G. Pathophysiology of Myocardial Infarction. Herz Kardiovaskuläre Erkrankungen. 2008 Mar;33(2):88–100.
14. Cabello JB, Burls A, Emparanza JI, Bayliss SE, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews. 2016 Dec 19;12(12).
15. Fu S, Lv X, Fang Q, Liu Z. Oxygen therapy for acute myocardial infarction: A systematic review and meta-analysis. International Journal of Nursing Studies. 2017 Sep;74:8–14.
16. Hyperbaric Oxygen Therapy Following Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Cardiovascular Revascularization Medicine [Internet]. 2021 Jun 1 [cited 2023 Dec 12];27:14–9.
17. Hofmann R, Witt N, Lagerqvist B, Jernberg T, Lindahl B, Erlinge D, et al. Oxygen therapy in ST-elevation myocardial infarction. European Heart Journal. 2018 Jun 14;39(29):2730–9.
18. Ferreira JC, Mochly-Rosen D. Nitroglycerin use in myocardial infarction patients. Circ J. 2012;76(1):15-21. doi: 10.1253/circj.cj-11-1133. Epub 2011 Nov 1. PMID: 22040938; PMCID: PMC3527093.
19. Rujic D, Nielsen ML, Veien KT, Pareek M. Nitroglycerine Induced Acute Myocardial Infarction in a Patient with Myocardial Bridging. Case Reports in Cardiology. 2014;2014:1–3.
20. Zvara DA, Groban L, Rogers AT, Prielipp RC, Murphy B, Hines M, et al. Prophylactic nitroglycerin did not reduce myocardial ischemia during accelerated recovery management of coronary artery bypass graft surgery patients. Journal of Cardiothoracic and Vascular Anesthesia. 2000 Oct;14(5):571–5.
21. Bainey KR, Armstrong PW. Clinical perspectives on reperfusion injury in acute myocardial infarction. American Heart Journal. 2014 May;167(5):637–45.
22. Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST-elevation acute myocardial infarction. Progress in Cardiovascular Diseases. 2004 Sep;47(2):131–57.

23. Shi Z, Hsieh KS, Wang H, Yang X, Zhang L, Kong X, et al. Further Review of Aspirin in the Treatment of Kawasaki Disease. Asian Journal of Pediatric Research. 2022 Nov 5;13–20.
24. Stolarek W, Kasprzak M, Sikora J, Siemińska E, Grześk G. High on-treatment platelet reactivity to aspirin in patients after myocardial infarction. Biomedicine & Pharmacotherapy. 2022 Mar;147:112618.
25. Sehanobish E, Asad M, Barbi M, Porcelli SA, Jerschow E. Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease. Frontiers in Immunology. 2021 Jun 25;12.
26. Hennekens CH, Dalen JE. Aspirin in the Treatment and Prevention of Cardiovascular Disease: Past and Current Perspectives and Future Directions. The American Journal of Medicine. 2013 May;126(5):373–8.
27. Beigel R, Zaza Iakobishvili, Nir S, Amit Segev, Witberg G, Doron Zahger, et al. Real-World Use of Novel P2Y12 Inhibitors in Patients with Acute Myocardial Infarction: A Treatment Paradox. Cardiology. 2016 Aug 23;136(1):21–8.
28. Alexopoulos D, Xanthopoulou I, Goudevenos J. Effects of P2Y12 Receptor Inhibition in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology. 2014 Jun;113(12):2064–9.
29. Bansal SS, Chetan. A Contemporary Role of Beta Blockers in Myocardial Infarction. Cardiology and Angiology: An International Journal. 2022 Apr 27;23–7.
30. Evans, T Should beta-blockers be recommended after myocardial infarction when left ventricular ejection fraction is normal? [Internet]. Vol. 109, typeset.io. 2023.
31. Vítovec J, Špinar J, Špinarová L. Beta blockers after myocardial infarction and chronic coronary heart disease. Vnitřní lékařství. 2022 Apr 26;68(3):178–80.
32. Safi S, Sethi NJ, Korang SK, Nielsen EE, Feinberg J, Gluud C, et al. Beta-blockers in patients without heart failure after myocardial infarction. The Cochrane Database of Systematic Reviews [Internet]. 2021 Nov 5 [cited 2021 Nov 19];11:CD012565.
33. van Gameren M, Lemmert ME, Wilschut JM, Daemen J, De Jaegere PPT, Zijlstra F, et al. An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction. Expert Opinion on Pharmacotherapy. 2018 Sep 2;19(13):1441–50.
34. Onwordi EN, Gamal A, Zaman A. Anticoagulant Therapy for Acute Coronary Syndromes. Interventional Cardiology Review . 2018;13(2):1.
35. Larson EA, German DM, Shatzel J, DeLoughery TG. Anticoagulation in the cardiac patient: A concise review. European Journal of Haematology. 2018 Nov 14;102(1):3–19.
36. Irving S. WrightThe Discontinuance of Anticoagulant Therapy. typesetio .2017 Jan 1 [cited 2023 Dec 12];
37. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Erratum in: Lancet. 2008 Jun 21;371(9630):2084. PMID: 16214597.
38. Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R. Atorvastatin has an important acute anti-inflammatory effect in

patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005 Mar;149(3):451-7. doi: 10.1016/j.ahj.2004.07.041. PMID: 15864233.

39. Han X, Zhang Y, Yin L, Zhang L, Wang Y, Zhang H, Li B. Statin in the treatment of patients with myocardial infarction: A meta-analysis. Medicine (Baltimore). 2018 Mar;97(12):e0167. doi: 10.1097/MD.0000000000010167. PMID: 29561426; PMCID: PMC5895306.
40. Jeong HS, Hong SJ. Benefit of Early Statin Therapy in Acute Myocardial Infarction in Korea. Korean Circ J. 2019 May;49(5):434-436. doi: 10.4070/kcj.2019.0045. Epub 2019 Mar 11. PMID: 30891965; PMCID: P40.Impact of ACE Inhibitors and ARBs-related Adverse Drug Reactions Consultations on Patients' Clinical Outcomes: A Cohort Study in UK Primary Care. British Journal of General Practice . 2023 Jul 4 [cited 2023 Dec 13];BJGP.2023.0153–3.
41. Alex K, Santillano S. Are ACE inhibitors more effective than ARBs in reducing cardiovascular events in hypertensive patients with diabetes? Evidence-Based Practice. 2020 Aug 19;Publish Ahead of Print.
42. Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, et al. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents. Angiology. 2019 Nov 6;71(2):139–49.

HOW TO CITE: Satish S., Aravind Babu C.*, Advancements In Pharmacotherapy For Myocardial Infarction: A Comprehensive Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 12, 534-542. https://doi.org/10.5281/zenodo.10405404